Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry

By sjmartinez • May 21, 2024

Larsen CP, Vincenti F, D Kou T, Shadur CA, Bresnahan B, Jordan SC, Woodle ES, Goes N, Vella J, Wojciechowski D, Polinsky MS, Gomez-Caminero A. Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry. Transplant Direct. 2024 May 17;10(6):e1644. doi: 10.1097/TXD.0000000000001644. PMID: 38769981; PMCID: PMC11104716.

Tags: Cedars Sinai DoM, Nephrology, Publications

Related Posts

Let distortion-guided restoration: a physics-informed learning framework to correct prostate diffusion MRI artifacts

Long Z, Binesh N, Wang L, Malaji AV, Yang CC, Sun H, Saouaf R, Daskivich T, Kim H, Xie Y, Li D, Yang HJ. Let[...]

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

McDonald CM, Villa C, Soslow JH, Maharry K, Hogan N, Binks M, Berth KC, Elliott KA, Taylor M, Hor KN, Signorovich J, Henricson EK, Phan[...]

Hidden risk in normal myocardial perfusion scans: AI-detected proximal coronary calcium on CT attenuation maps improves prognosis

Zhou J, Miller RJH, Shanbhag A, Killekar A, Han D, Patel KK, Pieszko K, Yi J, Urs MK, Ramirez G, Lemley M, Kavanagh PB, Liang[...]